Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Kaysville, Utah, USA
Future directions lie in the development of patient-specific, stimulus-responsive hydrogel platforms capable of delivering chemotherapeutics, radiosensitizers, and immunomodulators in a controlled, spatially precise manner
Cloud, Florida Individual results may vary
A successful strategy should: Invest in high-growth therapy areas (GLP-1, combo antihypertensives) Optimize portfolio mix to phase out declining products Adopt a patient-centric, digital-enabled chronic care model #PharmaMarket #IPM #MarketIntelligence #ChronicDiseases #GLP1 #Insulin #PharmaStrategy #CompetitiveIntelligence #MarketTrends To view or add a comment, sign in Market Insight | November IQVIA Data The November IQVIA data clearly highlights a structural shift in diabetes management
US$ 20.84
US$ 27.62
US$ 23.48
US$ 20.99
US$ 25.91
